Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | May 24, 2017 | May 25, 2017 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director · CHAIRMAN & CEO | September 01, 2026 | September 03, 2026 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | June 08, 2017 | September 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date May 24, 2017 · Filed May 25, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.13 · Expires 2027-05-24 | Direct | 30,000 |
Reported balance
After 2017-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-24 · Grant · Acquired 30,000 · Balance 30,000 F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2: Vests 1/12th per month over twelve months beginning June 24, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
F2: Vests 1/12th per month over twelve months beginning June 24, 2017.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 86,165 |
Reported balance
After 2026-09-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-01 · Exercise / conversion · Acquired 9,991 · Balance 86,165 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 92,646 |
Reported balance
After 2026-09-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-01 · Exercise / conversion · Acquired 6,481 · Balance 92,646 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 98,883 |
Reported balance
After 2026-09-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Acquired 6,237 · Balance 98,883 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 107,492 |
Reported balance
After 2026-09-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-01 · Exercise / conversion · Acquired 8,609 · Balance 107,492 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 92,348 |
Reported balance
After 2026-09-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-09-01 · Tax withholding · Disposed 15,144 · Balance 92,348 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 30,050 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Grant · Acquired 30,050 · Balance 30,050 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 25,826 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 8,609 · Balance 25,826 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 12,475 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 6,237 · Balance 12,475 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 6,481 |
Reported balance
After 2026-09-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-01 · Exercise / conversion · Disposed 6,481 · Balance 6,481 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Exercise / conversion · Disposed 9,991 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 120,150 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Grant · Acquired 120,150 · Balance 120,150 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 | 109,795 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 109,795 |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 | 51,794 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 51,794 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Syros Pharmaceuticals, Inc.
Report date June 08, 2017 · Filed September 22, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2027-06-07 | Direct | 11,000 |
Reported balance
After 2017-06-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-06-08 · Grant · Acquired 11,000 · Balance 11,000 F2: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person. F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date.
F2: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2024 Filed Mar 11, 2024 23:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 65,012 | $21.02 | $1,366,552.24 |
DisclosureSEC source: 0001415889-24-007569 · form4-03112024_110346.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Indirect · Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.00 and $21.145. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 06, 2024 Filed Mar 6, 2024 22:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 5,582 | $21.00 | $117,222.00 |
DisclosureSEC source: 0001415889-24-007083 · form4-03062024_100330.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Indirect · Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 65,012 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 3,336 | $22.00 | $73,392.00 |
DisclosureSEC source: 0001415889-24-007083 · form4-03062024_100330.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Indirect · Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 70,594 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 9,406 | $21.31 | $200,441.86 |
DisclosureSEC source: 0001415889-24-007083 · form4-03062024_100330.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Indirect · Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 73,930 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.00 and $21.785. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013044 · form4-09062023_110936.xml · derivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,138 Underlying: Class A Common Share · 6,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 2,187 | $17.76 | $38,841.12 |
DisclosureSEC source: 0001415889-23-013044 · form4-09062023_110936.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,516 Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 6,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013044 · form4-09062023_110936.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 155,500 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001415889-23-013044 · form4-09062023_110936.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,500 Underlying: Class A Common Share · 155,500 shares Expires 2033-08-31 F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 25,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013044 · form4-09062023_110936.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,925 Underlying: Class A Common Share · 25,925 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023. F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 9,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013044 · form4-09062023_110936.xml · derivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,975 Underlying: Class A Common Share · 9,992 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 4,432 | $17.76 | $78,712.32 |
DisclosureSEC source: 0001415889-23-013044 · form4-09062023_110936.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,134 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 9,992 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013044 · form4-09062023_110936.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 9,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-006442 · form4-04112023_090418.xml · derivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,975 Underlying: Class A Common Share · 9,992 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 2,933 | $10.71 | $31,412.43 |
DisclosureSEC source: 0001415889-23-006442 · form4-04112023_090418.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,574 Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 9,992 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-006442 · form4-04112023_090418.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 25,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005787 · form4-04032023_040405.xml · derivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,925 Underlying: Class A Common Share · 25,925 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 155,500 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-23-005787 · form4-04032023_040405.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,500 Underlying: Class A Common Share · 155,500 shares Expires 2033-03-31 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 12,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005233 · form4-03202023_090347.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 12,002 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. F3 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 3,523 | $11.12 | $39,175.76 |
DisclosureSEC source: 0001415889-23-005233 · form4-03202023_090347.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,515 Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 12,002 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005233 · form4-03202023_090347.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005233 · form4-03202023_090347.xml · derivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,138 Underlying: Class A Common Share · 6,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,929 | $11.46 | $22,106.34 |
DisclosureSEC source: 0001415889-23-005233 · form4-03202023_090347.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,036 Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 6,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005233 · form4-03202023_090347.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:11 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009352 · form4-09062022_010915.xml · derivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,707 Underlying: Class A Common Share · 6,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:11 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,929 | $11.44 | $22,067.76 |
DisclosureSEC source: 0001415889-22-009352 · form4-09062022_010915.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,396 Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:11 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 6,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-009352 · form4-09062022_010915.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:11 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 39,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009352 · form4-09062022_010915.xml · derivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,967 Underlying: Class A Common Share · 39,967 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:11 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 239,795 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001415889-22-009352 · form4-09062022_010915.xml · derivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,795 Underlying: Class A Common Share · 239,795 shares Expires 2032-08-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 39,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003994 · form4-04112022_040424.xml · derivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,967 Underlying: Class A Common Share · 39,967 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 239,795 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-22-003994 · form4-04112022_040424.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,795 Underlying: Class A Common Share · 239,795 shares Expires 2032-04-06 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 18,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003287 · form4-03232022_040333.xml · derivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 18,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 5,446 | $10.98 | $59,797.08 |
DisclosureSEC source: 0001415889-22-003287 · form4-03232022_040333.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,756 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 18,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-003287 · form4-03232022_040333.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002326 · edgar.xml · derivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,707 Underlying: Class A Common Share · 6,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,922 | $10.13 | $19,469.86 |
DisclosureSEC source: 0001179110-22-002326 · edgar.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,647 Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 6,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002326 · edgar.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 26,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008644 · edgar.xml · derivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,276 Underlying: Class A Common Shares · 26,276 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 157,658 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001179110-21-008644 · edgar.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,658 Underlying: Class A Common Shares · 157,658 shares Expires 2031-09-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. Read SEC document |
| March 20, 2021 Filed Mar 23, 2021 21:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 12,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003729 · edgar.xml · derivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,002 Underlying: Class A Common Shares · 12,002 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. F3 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. Read SEC document |
| March 20, 2021 Filed Mar 23, 2021 21:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 18,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003729 · edgar.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,555 Underlying: Class A Common Shares · 18,555 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 26,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003616 · edgar.xml · derivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,276 Underlying: Class A Common Shares · 26,276 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 157,658 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001179110-21-003616 · edgar.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,658 Underlying: Class A Common Shares · 157,658 shares Expires 2031-03-15 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is March 16, 2021. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 1,600 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · derivative · entry 13 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,271 Underlying: Class A Common Shares · 1,600 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 1,137 | $23.07 | $26,230.59 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · nonDerivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 83,336 F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. F8 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $23.00 to $23.15. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 1,600 | $23.06 | $36,896.00 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · nonDerivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. F7 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $23.00 to $23.18. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 1,600 | $1.59 | $2,544.00 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · nonDerivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 20,401 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · derivative · entry 12 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,871 Underlying: Class A Common Shares · 20,401 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 23,569 | $23.08 | $543,972.52 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · nonDerivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 84,473 F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. F6 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $23.00 to $23.27. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 20,401 | $23.04 | $470,039.04 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $23.00 to $23.24. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 20,401 | $1.59 | $32,437.59 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.